Athira Pharma, Inc. (ATHA) Made Misleading Statements Regarding the Research Backing its Drug Candidates   On June 17, 2021, Athira issued a press release announcing that the Company’s board of

AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA   The Defendants made false and/or misleading statements and/or failed to disclose that: (i) AcelRx had

DiDi Global, Inc. (DIDI) Failed to Comply with Privacy Protection Laws   The Company sold approximately 316,800,000 shares at $14.00 per share in the IPO, for proceeds of $4,333.1 million. 

DraftKings, Inc. (DKNG) Made Misstatements Regarding its Business Prospects DraftKings, Inc. was incorporated through a business combination with DEAC, a special purpose acquisition company.  In the process, the Company also

Rekor Systems, Inc. (REKR) Made Misstatements Regarding its Business Prospects During the class period, Rekor touted the lucrative prospects of its uninsured vehicle enforcement diversion (“UVED”) partnership with the State

Array Technologies, Inc. (ARRY) Failed to Disclose Rising Costs Would Have an Adverse Effect on its Business Operations Array’s Offering Materials stated that one of the Company’s strengths related to

Skillz Inc. (SKLZ) Made Misstatements Regarding its Purported Financial Condition and Prospects     Flying Eagle Acquisition Corp., a special purpose acquisition corporation, and Skillz consummated their merger on December 16,

AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA   During the relevant period, defendants made false and/or misleading statements and/or failed to disclose that: